Literature DB >> 20713152

Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons.

Hyun-Jung Kim1.   

Abstract

Parkinson's disease (PD) involves the loss of dopamine (DA) neurons, making it the most expected neurodegenerative disease to be treated by cell replacement therapy. Stem cells are a promising source for cell replacement therapy due to their ability to self-renew and their pluripotency/multipotency that allows them to generate various types of cells. However, it is challenging to derive midbrain DA neurons from stem cells. Thus, in this review, I will discuss the molecular factors that are known to play critical roles in the generation and survival of DA neurons. The developmental process of DA neurons and functions of extrinsic soluble factors and homeodomain proteins, forkhead box proteins, proneural genes, Nurr1 and genes involved in epigenetic control are discussed. In addition, different types of stem cells that have potential for future cell replacement therapy are reviewed.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713152     DOI: 10.1016/j.bbadis.2010.08.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

1.  Microtissue engineered constructs with living axons for targeted nervous system reconstruction.

Authors:  D Kacy Cullen; Min D Tang-Schomer; Laura A Struzyna; Ankur R Patel; Victoria E Johnson; John A Wolf; Douglas H Smith
Journal:  Tissue Eng Part A       Date:  2012-08-17       Impact factor: 3.845

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Rebuilding Brain Circuitry with Living Micro-Tissue Engineered Neural Networks.

Authors:  Laura A Struzyna; John A Wolf; Constance J Mietus; Dayo O Adewole; H Isaac Chen; Douglas H Smith; D Kacy Cullen
Journal:  Tissue Eng Part A       Date:  2015-10-23       Impact factor: 3.845

Review 4.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

Review 5.  Dopamine cell transplantation in Parkinson's disease: challenge and perspective.

Authors:  Yilong Ma; Shichun Peng; Vijay Dhawan; David Eidelberg
Journal:  Br Med Bull       Date:  2011-08-28       Impact factor: 4.291

Review 6.  Stem cell technology for neurodegenerative diseases.

Authors:  J Simon Lunn; Stacey A Sakowski; Junguk Hur; Eva L Feldman
Journal:  Ann Neurol       Date:  2011-09       Impact factor: 10.422

7.  Nato3 integrates with the Shh-Foxa2 transcriptional network regulating the differentiation of midbrain dopaminergic neurons.

Authors:  Einat Nissim-Eliraz; Sophie Zisman; Omri Schatz; Nissim Ben-Arie
Journal:  J Mol Neurosci       Date:  2012-12-21       Impact factor: 3.444

8.  Mitogen-activated protein kinase phosphatase (MKP)-1 as a neuroprotective agent: promotion of the morphological development of midbrain dopaminergic neurons.

Authors:  Louise M Collins; Gerard W O'Keeffe; Caitriona M Long-Smith; Sean L Wyatt; Aideen M Sullivan; André Toulouse; Yvonne M Nolan
Journal:  Neuromolecular Med       Date:  2013-04-13       Impact factor: 3.843

9.  Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.

Authors:  Laura A Struzyna; Kevin D Browne; Zachary D Brodnik; Justin C Burrell; James P Harris; H Isaac Chen; John A Wolf; Kate V Panzer; James Lim; John E Duda; Rodrigo A España; D Kacy Cullen
Journal:  J Tissue Eng Regen Med       Date:  2018-06-03       Impact factor: 3.963

10.  Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain.

Authors:  J P Harris; L A Struzyna; P L Murphy; D O Adewole; E Kuo; D K Cullen
Journal:  J Neural Eng       Date:  2016-01-13       Impact factor: 5.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.